Navigation Links
Hissey Kientz Concerned That Patients Have Not Been Provided With Crucial Information About Digitek Recall Despite the Dangers of Digoxin Toxicity

Hissey Kientz, LLP is concerned that despite a recent recall notice for the heart drug Digitek, the drug’s manufacturer has failed to provide any additional information on how long the heart medication was being improperly manufactured. According to a press release issued by the manufacturer, some Digitek tablets may have been manufactured at double their normal strength, meaning that patients could receive a double dose of the drug, leading to an overdose. A Digitek overdose could lead to severe side effects, including heart attack, stroke or death.

Austin, TX (Vocus) August 16, 2008 -- The law firm of Hissey Kientz, LLP is concerned over recent reports that many heart patients may not have been fully informed by the drug’s manufacturer about problems with the heart drug Digitek. Drugmaker Actavis Totowa issued a nationwide recall notice for the heart drug [Digitek] (digoxin) on April 25, 2008.

In a press release announcing the recall notice, the company stated that some Digitek tablets may have been manufactured at twice their normal thickness, meaning that patients could receive a double-dose of the drug. This increased exposure could cause patients to suffer an overdose, leading to heart attack, stroke or death.

But according to a statement by the Food and Drug Administration published on May 1, 2008, since the Digitek recall was issued doctors and patients have received no additional information on how long the drug was being produced at twice the normal strength. The public has also not been notified on how many lots of the heart medication were improperly manufactured and when this problem was first detected.

“Actavis has a responsibility to provide consumers with all the available safety information about the manufacturing problems connected with the [Digitek recall],” says attorney Mike Hissey with Hissey Kientz, LLP in Austin, Texas. “The public has a right to know how long this problem has been going on and how many patients could be affected. Many consumers were only made aware of the problems with Digitek when their pharmacist or doctor told them about the recall notice.”

Digitek is prescribed to patients with heart problems in order to treat congestive heart failure, an irregular heartbeat or other symptoms. Digitek is a form of the heart medication digitalis, which helps to strengthen the beating of the heart muscles and relieve the symptoms of patients with these conditions. It is also known generically as digoxin.

However, when administered in too high of a dose, digoxin drugs such as Digitek may cause digoxin toxicity, resulting in an overdose. Symptoms of a [Digitek overdose] include unusual changes in vision, dizziness, irregular heartbeat, abnormally low blood pressure or heart rate, nausea, vomiting or other symptoms. In severe cases, digoxin toxicity can lead to a heart attack or stroke, which can result in death.

The FDA sent warning letters to Actavis in September 2006 and February 2007 after the agency uncovered manufacturing problems at the plant where Digitek is produced. The FDA stated in these letters that because of quality control problems at the plant, drugs made there were “adulterated,” making it impossible to determine if they were being manufactured at the correct strength.

Actavis also issued a recall notice on August 1, 2008 for every single drug produced at the New Jersey plant where Digitek was manufactured. The recall notices were issued after an FDA inspection earlier this year revealed that the company had continued to violate “standards for good manufacturing practices,” according to a statement by the company, even after it had received two previous warning letters for similar infractions.

Digitek tablets manufactured by Actavis Totowa were distributed by UDL Laboratories and Mylan Pharmaceuticals. Tablets distributed by UDL were sold under the label “UDL,” while those distributed by Mylan were sold under the name “Bertek.” Patients who were taking Digitek before the recall notice was issued may wish to speak with their doctors to discuss alternate forms of treatment.

Dozens of patients who suffered severe injuries after using Digitek have filed lawsuits against the manufacturer and distributors of the drug. These lawsuits have alleged that Digitek was dangerously and defectively manufactured, putting patients at risk of severe and potentially fatal side effects due to an overdose.

About Hissey Kientz, LLP [Hissey Kientz, LLP] is currently accepting cases involving individuals who may have been injured as a result of a Digitek overdose. Hissey Kientz, LLP also represents those who contracted mesothelioma or lung cancer as a result of asbestos exposure, and those injured by the Ortho Evra patch, Trasylol, the Composix Kugel mesh patch, the Duragesic patch (fentanyl), gadolinium MRI contrast dyes or other defective drugs and devices. To learn more about the firm and other drug cases, visit Hissey Kientz, LLP ( or call toll-free at (866) 275-4454.


Read the full story at

Source: PRWeb
Copyright©2008 Vocus, Inc.
All rights reserved  

Related medicine news :

1. New Survey Shows Americans are Still Concerned About Food Safety, Yet Still Not Smart About What They Like to Eat
2. AGD Concerned With Presidential Veto of SCHIP Reauthorization Bill
3. National Nature Made(R) Survey Finds U.S. Adults Are Concerned About Heart Disease but May not be Managing Their Risk
4. AACN Concerned That the Presidents FY 2009 Budget Request Will Prolong the Nursing and Nurse Faculty Shortage
5. New Survey Shows African-Americans Are Concerned With Heart Health but Unaware of Link to Brain Health
6. National Religious Coalition Deeply Concerned by HHS Secretarys Disregard for Womens Reproductive Health
7. Operating Room Nurses are Concerned about Complications Associated with Powdered Gloves
8. UNICEF Concerned About Emotional Distress of Children in Myanmar
9. Survey: Maryland Voters Concerned About Health Care
10. Fluctuating eye pressure associated with visual field deterioration in glaucoma patients
11. Comparison of obstetric outcomes between on-call and patients own obstetricians
Post Your Comments:
Related Image:
Hissey Kientz Concerned That Patients Have Not Been Provided With Crucial Information About Digitek Recall Despite the Dangers of Digoxin Toxicity
(Date:11/25/2015)... ... 2015 , ... As part of a global movement to ... together who want to combine talents and resources to help create sustainable communities ... The non-profit launched its first major fundraiser on November 6, 2015 at Bent ...
(Date:11/25/2015)... NV (PRWEB) , ... November 25, 2015 , ... Dr. ... patients to learn more about hair loss treatment with the Capillus272™ Pro laser therapy ... effective solution for thicker and fuller hair, without the need for surgery, prescription pills, ...
(Date:11/25/2015)... ... November 25, 2015 , ... ... people across the country to celebrate their sobriety and show through pictures what ... “before and after” photos this Thanksgiving with the hashtag #FacesOfGratitude on their Facebook, ...
(Date:11/25/2015)... ... November 25, 2015 , ... On November 23rd 2015 Cozy ... personal heating products business. Cozy Products explains what this means for business moving ... well with the Cozy Products business model: to sell personal heaters that reduce energy ...
(Date:11/25/2015)... ... November 25, 2015 , ... In an ongoing Clinical Study conducted by ... Chicago, IL, UV Angel is evaluating the efficacy of its product and its disinfection ... (totaling 30 beds) from May 2014 through October 2015 at a 360-bed, acute-care, academic ...
Breaking Medicine News(10 mins):
(Date:11/26/2015)... , Nederland, November 26, 2015 /PRNewswire/ ... --> Een nieuwe aanpak combineert immunotherapie ... gevorderde kanker. ) ... -->      (Photo: ... het Leids Universitair Medisch Centrum (LUMC) ...
(Date:11/26/2015)... DUBLIN , November 26, 2015 /PRNewswire/ ... the addition of the "2016 Future ... Drugs of Abuse Testing Market: Supplier Shares, ... report to their offering. --> ... of the "2016 Future Horizons and ...
(Date:11/26/2015)... , November 26, 2015 /PRNewswire/ ... announced the addition of the  "2016 ... the European Therapeutic Drug Monitoring (TDM) ... Competitive Intelligence, Emerging Opportunities"  report to ... ) has announced the addition of ...
Breaking Medicine Technology: